Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Allbirds, Inc. (BIRD) Reports Q1 Loss, Tops Revenue Estimates
Allbirds, Inc. (BIRD) Reports Q1 Loss, Tops Revenue Estimates

Allbirds, Inc. (BIRD) came out with a quarterly loss of $2.73 per share versus the Zacks Consensus Estimate of a loss of $3.85. This compares to loss of $3.60 per share a year ago. These figures are

Applied Optoelectronics (AAOI) Reports Q1 Loss, Tops Revenue Estimates
Applied Optoelectronics (AAOI) Reports Q1 Loss, Tops Revenue Estimates

Applied Optoelectronics (AAOI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.31 per share a year ago. These

Trex (TREX) Tops Q1 Earnings and Revenue Estimates
Trex (TREX) Tops Q1 Earnings and Revenue Estimates

Trex (TREX) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.82 per share a year ago. These figures are

Solventum (SOLV) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Solventum (SOLV) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended March 2025, Solventum (SOLV) reported revenue of $2.07 billion, up 2.7% over the same period last year. EPS came in at $1.34, compared to $2.08 in the year-ago quarter.

The

Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics

Collegium Pharmaceutical (COLL) reported $177.76 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 22.7%. EPS of $1.49 for the same period compares to

Microchip Technology (MCHP) Q4 Earnings and Revenues Beat Estimates
Microchip Technology (MCHP) Q4 Earnings and Revenues Beat Estimates

Microchip Technology (MCHP) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.57 per share a year ago

Compared to Estimates, Olo (OLO) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, Olo (OLO) Q1 Earnings: A Look at Key Metrics

For the quarter ended March 2025, Olo Inc. (OLO) reported revenue of $80.68 million, up 21.3% over the same period last year. EPS came in at $0.07, compared to $0.05 in the year-ago quarter.

The

Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say
Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say

Insulet (PODD) reported $569 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 28.8%. EPS of $1.02 for the same period compares to $0.73 a year ago.

The

Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year

Research Solutions Inc. (RSSS) Meets Q3 Earnings Estimates
Research Solutions Inc. (RSSS) Meets Q3 Earnings Estimates

Research Solutions Inc. (RSSS) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to break-even earnings per share a year ago. These

Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say
Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say

Pacira (PCRX) reported $168.92 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 1.1%. EPS of $0.62 for the same period compares to $0.62 a year ago.

The

DoubleVerify Holdings (DV) Q1 Earnings Miss Estimates
DoubleVerify Holdings (DV) Q1 Earnings Miss Estimates

DoubleVerify Holdings (DV) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.04 per share a year ago

Akamai Technologies (AKAM) Reports Q1 Earnings: What Key Metrics Have to Say
Akamai Technologies (AKAM) Reports Q1 Earnings: What Key Metrics Have to Say

For the quarter ended March 2025, Akamai Technologies (AKAM) reported revenue of $1.02 billion, up 2.9% over the same period last year. EPS came in at $1.70, compared to $1.64 in the year-ago

Dropbox (DBX) Q1 Earnings and Revenues Surpass Estimates
Dropbox (DBX) Q1 Earnings and Revenues Surpass Estimates

Dropbox (DBX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.58 per share a year ago. These figures are

Leslie's, Inc. (LESL) Reports Q2 Loss, Misses Revenue Estimates
Leslie's, Inc. (LESL) Reports Q2 Loss, Misses Revenue Estimates

Leslie's, Inc. (LESL) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.17 per share a year ago. These figures are

Here's What Key Metrics Tell Us About Lyft (LYFT) Q1 Earnings
Here's What Key Metrics Tell Us About Lyft (LYFT) Q1 Earnings

For the quarter ended March 2025, Lyft (LYFT) reported revenue of $1.45 billion, up 13.5% over the same period last year. EPS came in at $0.19, compared to $0.15 in the year-ago quarter.

The

Federal Realty Investment Trust (FRT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Federal Realty Investment Trust (FRT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended March 2025, Federal Realty Investment Trust (FRT) reported revenue of $309.15 million, up 6.1% over the same period last year. EPS came in at $1.70, compared to $0.66 in the

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.42 per share a year ago. These

JFrog Ltd. (FROG) Q1 Earnings and Revenues Surpass Estimates
JFrog Ltd. (FROG) Q1 Earnings and Revenues Surpass Estimates

JFrog Ltd. (FROG) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.16 per share a year ago. These figures

Sensata (ST) Q1 Earnings and Revenues Beat Estimates
Sensata (ST) Q1 Earnings and Revenues Beat Estimates

Sensata (ST) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.89 per share a year ago. These figures are

Xponential Fitness (XPOF) Reports Q1 Loss, Tops Revenue Estimates
Xponential Fitness (XPOF) Reports Q1 Loss, Tops Revenue Estimates

Xponential Fitness (XPOF) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of $0.15. This compares to earnings of $0.16 per share a year ago. These figures are

ZipRecruiter, Inc. (ZIP) Reports Q1 Loss, Tops Revenue Estimates
ZipRecruiter, Inc. (ZIP) Reports Q1 Loss, Tops Revenue Estimates

ZipRecruiter, Inc. (ZIP) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.07 per share a year ago. These figures

BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates
BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.19 per share a year

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.46 per share a year ago. These figures are

Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.22 per share a year ago. These figures